Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study
Early administration of combination therapy with a direct antiviral and sotrovimab seems to be effective in preventing hospitalization, progression to severe COVID-19, and development of prolonged/persisting SARS-CoV-2 infection in immunocompromised patients.
Authors
- Francesco Grimaldi (ORCID: https://orcid.org/0000-0003-4365-9406)
- Alessia D’Agostino (ORCID: https://orcid.org/0000-0002-4309-1083)
- Giulio Viceconte (ORCID: https://orcid.org/0000-0003-3989-2520)
- Antonio Riccardo Buonomo (ORCID: https://orcid.org/0000-0002-4378-8366)
- Angela Gravetti
- F. Trastulli
- Riccardo Scotto (ORCID: https://orcid.org/0000-0002-0178-2986)
- Ivan Gentile (ORCID: https://orcid.org/0000-0002-5199-8451)
- Simona Mercinelli
- Marcello Moccia (ORCID: https://orcid.org/0000-0003-2613-3090)
- S. Palmieri
- Maria Silvitelli
- Daria Pietroluongo
- F. M. Cuccurullo
Institutions
- Ospedale Antonio Cardarelli (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1080/07853890.2024.2439541
- Citations
- 6
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.33